The emerging role of selenium metabolic pathways in cancer: New therapeutic targets for cancer.

Autor: Kalimuthu K; Department of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India., Keerthana CK; Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India., Mohan M; College of Pharmacy, University of Georgia, Athens, Georgia, USA.; VAXIGEN International Research Center Private Limited, Coimbatore, India., Arivalagan J; Department of Chemistry, Molecular Biosciences and Proteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA., Christyraj JRSS; Regeneration and Stem Cell Biology Lab, Centre for Molecular and Nanomedical Sciences, International Research Centre, Sathyabama Institute of Science and Technology, Chennai, Tamilnadu, India., Firer MA; Department of Chemical Engineering, Ariel University, Ariel, Israel.; Adelson School of Medicine, Ariel University, Ariel, Israel.; Ariel Center for Applied Cancer Research, Ariel University, Ariel, Israel., Choudry MHA; Department of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Anto RJ; Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India., Lee YJ; Department of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Journal of cellular biochemistry [J Cell Biochem] 2022 Mar; Vol. 123 (3), pp. 532-542. Date of Electronic Publication: 2021 Dec 21.
DOI: 10.1002/jcb.30196
Abstrakt: Selenium (Se) is incorporated into the body via the selenocysteine (Sec) biosynthesis pathway, which is critical in the synthesis of selenoproteins, such as glutathione peroxidases and thioredoxin reductases. Selenoproteins, which play a key role in several biological processes, including ferroptosis, drug resistance, endoplasmic reticulum stress, and epigenetic processes, are guided by Se uptake. In this review, we critically analyze the molecular mechanisms of Se metabolism and its potential as a therapeutic target for cancer. Sec insertion sequence binding protein 2 (SECISBP2), which is a positive regulator for the expression of selenoproteins, would be a novel prognostic predictor and an alternate target for cancer. We highlight strategies that attempt to develop a novel Se metabolism-based approach to uncover a new metabolic drug target for cancer therapy. Moreover, we expect extensive clinical use of SECISBP2 as a specific biomarker in cancer therapy in the near future. Of note, scientists face additional challenges in conducting successful research, including investigations on anticancer peptides to target SECISBP2 intracellular protein.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: